The CV values were below about 5%. The recovery of M-4 was relatively poor, probably due to higher polarity. The reproducibility of the method was also assessed by the repeated analysis of urine samples from obstetric patients infused with Percamine S® in the spinal cord. As shown in Table I , the CV values were satisfactory for all compounds (below 7%). Thus, the method was proved to be reproducible.
Using this method, we determined the urinary excretion of dibucaine and its metabolites by obstetric patients infused with Percamine S® in the spinal cord. In Table II the urinary excretion of dibucaine and its metabolites during 10 h after administration is presented. In the early period a small amount of dibucaine was observed (about 0.02 mg), and thereafter the amount was very small. On the other hand, metabolites were excreted at an approximately constant rate during 10 h after dosing. Ranges of cumulative excreted M-4 and M-8 in seven patients were 5.2 19.9% and 2.2-5.6% of the dose, respectively. Dibucaine and M-10 were excreted in the ranges of 0.3 3.2% and 0.6-1.7%, respectively. The range of total urinary excretion was 9.1 28.3%, with an average of 16.2% of the dose. These values are reasonably consistent with the findings in male healthy volunteers receiving dibucaine orally (10 mg); total excretion during 9 h after dosing, averaged 12.6% of the dose.6) Fukui has also reported that only 1 2% of the dose was excreted as unchanged drug in the 0 12 h urine of patients infused with Percamine L (containing 0.5% dibucaine) in the spinal cord?) From these results, we consider that dibucaine is rapidly and extensively metabolized in humans.
In conclusion, we have developed a sensitive and specific method to determine dibucaine and its metabolites in urine under clinical conditions. 
